News

Gene Therapy SynCav1 Found to Extend Survival in ALS Mouse Model

Treatment with gene therapy candidate SynCav1 delayed disease onset and extended survival in a mouse model of amyotrophic lateral sclerosis (ALS), according to a new study. The experimental therapy aims to improve the survival of motor neurons in people with ALS irrespective of the underlying cause. “These data suggest that…

BrainStorm Plans to File for NurOwn Approval in US for ALS

Brainstorm Cell Therapeutics is preparing to file an application with the U.S. Food and Drug Administration (FDA) requesting approval of its cell-based therapy NurOwn for amyotrophic lateral sclerosis (ALS). The decision to submit a biologics license application was based on “the totality of the evidence from NurOwn’s clinical…

Initiative Makes Stem Cell Lines Available for Research Worldwide

A number of stem cell lines developed to better understand how certain genetic factors might contribute to amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases is now available to scientists worldwide. The cell lines were engineered by researchers at the National Institutes of Health Center for Alzheimer’s and Related…

Radicava Seen in Real-world Study to Prolong Survival With ALS

Real-world use of Radicava (edaravone) significantly prolongs survival in amyotrophic lateral sclerosis (ALS) patients, with people in the U.S. on the therapy living about six months longer than those not on this treatment, an analysis of Radicava’s use in clinical settings reported. The estimated probability of survival was greater…

ALS Link With Specific STMN2 Gene Mutation Challenged in Study

A mutation in the STMN2 gene that consists of an excessive repeat of two nucleotides, the building blocks of DNA, is not associated with the greater risk of amyotrophic lateral sclerosis (ALS), a new study reported. Its findings contradict previous research suggesting a link between this particular mutation and ALS. “Although the…